A Phase 2 interventional study of Miricorilant and Placebo in Antipsychotic-induced Weight Gain (AIWG), sponsored by Corcept Therapeutics. Completed at 27 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Corcept Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese adults with schizophrenia or bipolar disorder treated with antipsychotic medications.
This is a randomized, double-blind, placebo-controlled study that will assess the safety, efficacy, and PK of miricorilant in obese patients with schizophrenia or bipolar disorder who are currently taking oral or injectable atypical antipsychotic medication.
Patients who meet the criteria for the Study CORT118335-876 will be randomized on Day 1 to receive 600 mg miricorilant or placebo for 12 weeks.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 71 is close to the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 3 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 9 (28%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who meet the entry criteria will be randomized to receive 600 mg miricorilant for 12 weeks.
Drug: Miricorilant
Patients who meet the entry criteria will be randomized to receive placebo for 12 weeks.
Drug: Placebo
Miricorilant 600 mg (6 X 100 mg tablets) for once-daily oral dosing
Also known as: CORT118335
Placebo tablets for once-daily oral dosing
Change From Baseline in Body Weight at Week 12 for 600 mg Miricorilant Versus Placebo
Time frame: Baseline Day 1 and Week 12
Number of Patients With One or More Treatment-emergent Adverse Events
Time frame: Up to Follow-up Visit (Week 16)
Number of Patients With One or More Treatment-emergent Serious Adverse Events
Time frame: Up to Follow-up Visit (up to Week 16)
Number of Patients With One or More Treatment-emergent Adverse Events Leading to Early Study Discontinuation
Time frame: Up to Follow-up Visit (up to Week 16)
Percentage of Patients Achieving More Than or Equal to 5% Weight Loss
Time frame: Baseline Day 1 to Week 12
Change From Baseline in HOMA-IR at Week 12
HOMA-IR = \[fasting plasma glucose (mg/dL) X fasting insulin (µU/mL)\]/405. HOMA-IR is a method to evaluate insulin sensitivity. The HOMA-IR score should be ≤1.0 to be considered normal. A score \>1.9 indicates early insulin resistance and a score \>2.9 indicates significant insulin resistance.
Time frame: Baseline Day 1 and Week 12
Change From Baseline in Waist-to-hip Ratio at Week 12
Waist-to-hip ratio compares the circumference of the waist to the circumference of the hips. The ratio is calculated by dividing the waist measurement by the hip measurement, using the same units of measurement for both. A waist-to-hip ratio \<0.95 in men and \<0.80 in women is considered healthy.
Time frame: Baseline Day 1 and Week 12
| Milestone | Miricorilant 600 mg | Placebo |
|---|---|---|
| Started | 35 | 36 |
| Completed | 27 | 28 |
| Not completed | 8 | 8 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Lost to follow-up | 0 | 5 |
| Withdrew: Gaining weight without prohibited medication vyvanse | 1 | 0 |
| Withdrew: Not reporting for scheduled visits | 1 | 0 |
| Withdrew: Non-compliant with investigational product | 1 | 0 |
| kg | Miricorilant 600 mg | Placebo |
|---|---|---|
| Change From Baseline in Body Weight at Week 12 for 600 mg Miricorilant Versus Placebo | -0.98 ± 0.414 | -1.08 ± 0.415 |
| Participants | Miricorilant 600 mg | Placebo |
|---|---|---|
| Number of Patients With One or More Treatment-emergent Adverse Events | 16 | 18 |
| Participants | Miricorilant 600 mg | Placebo |
|---|---|---|
| Number of Patients With One or More Treatment-emergent Serious Adverse Events | 1 | 1 |
| Participants | Miricorilant 600 mg | Placebo |
|---|---|---|
| Number of Patients With One or More Treatment-emergent Adverse Events Leading to Early Study Discontinuation | 3 | 1 |
| Participants | Miricorilant 600 mg | Placebo |
|---|---|---|
| Percentage of Patients Achieving More Than or Equal to 5% Weight Loss | 2 | 3 |
HOMA-IR = \[fasting plasma glucose (mg/dL) X fasting insulin (µU/mL)\]/405. HOMA-IR is a method to evaluate insulin sensitivity. The HOMA-IR score should be ≤1.0 to be considered normal. A score \>1.9 indicates early insulin resistance and a score \>2.9 indicates significant insulin resistance.
| HOMA-IR score | Miricorilant 600 mg | Placebo |
|---|---|---|
| Change From Baseline in HOMA-IR at Week 12 | 1.080 (-2.020 to 3.780) | 0.890 (-0.970 to 2.400) |
Waist-to-hip ratio compares the circumference of the waist to the circumference of the hips. The ratio is calculated by dividing the waist measurement by the hip measurement, using the same units of measurement for both. A waist-to-hip ratio \<0.95 in men and \<0.80 in women is considered healthy.
| Ratio | Miricorilant 600 mg | Placebo |
|---|---|---|
| Change From Baseline in Waist-to-hip Ratio at Week 12 | 0.008 ± 0.0092 | 0.001 ± 0.0091 |
Collected over Baseline Day 1 to Week 16. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Miricorilant 600 mg | 0/35 (0%) | 1/35 (2.9%) | 12/35 (34.3%) |
| Placebo | 0/36 (0%) | 1/36 (2.8%) | 5/36 (13.9%) |
| Event | Miricorilant 600 mg | Placebo |
|---|---|---|
| Hyperthermia malignantGeneral disorders | 1/35 | 0/36 |
| Toxicity to various agentsInjury, poisoning and procedural complications | 1/35 | 0/36 |
| ManiaPsychiatric disorders | 0/35 | 1/36 |
| Event | Miricorilant 600 mg | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 5/35 | 0/36 |
| Alanine aminotransferase increasedInvestigations | 4/35 | 2/36 |
| NauseaGastrointestinal disorders | 3/35 | 0/36 |
| Aspartate aminotransferase increasedInvestigations | 3/35 | 1/36 |
| AkathisiaNervous system disorders | 2/35 | 0/36 |
| Orthostatic hypotensionVascular disorders | 2/35 | 0/36 |
| AnaemiaBlood and lymphatic system disorders | 0/35 | 2/36 |
| SomnolenceNervous system disorders | 0/35 | 2/36 |
All enrolled patients
| Age, Continuous(Years) | Miricorilant 600 mg | Placebo | Total |
|---|---|---|---|
| Mean | 43.9 ± 10.50 | 47.5 ± 11.78 | 45.7 ± 11.24 |
| Sex: Female, Male(Participants) | Miricorilant 600 mg | Placebo | Total |
|---|---|---|---|
| Female | 19 | 20 | 39 |
| Male | 16 | 16 | 32 |
| Ethnicity (NIH/OMB)(Participants) | Miricorilant 600 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 9 | 16 |
| Not Hispanic or Latino | 28 | 27 | 55 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Miricorilant 600 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 13 | 16 | 29 |
| White | 21 | 20 | 41 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Miricorilant 600 mg | Placebo | Total |
|---|---|---|---|
| United States | 35 | 36 | 71 |
| Body weight(kg) | Miricorilant 600 mg | Placebo | Total |
|---|---|---|---|
| Mean | 110.39 ± 20.01 | 107.69 ± 25.41 | 109.02 ± 22.79 |
| Homeostatic model assessment for insulin resistance (HOMA-IR)(HOMA-IR score) | Miricorilant 600 mg | Placebo | Total |
|---|---|---|---|
| Mean | 8.687 ± 5.71 | 8.463 ± 17.27 | 8.577 ± 13.24 |
| Waist-to-hip ratio(Ratio) | Miricorilant 600 mg | Placebo | Total |
|---|---|---|---|
| Mean | 1.032 ± 0.24 | 0.967 ± 0.10 | 0.999 ± 0.18 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2019 to primary completion in Jun 2022, 30 months.
Results were first posted in Sep 2024, 2 years 3 months after primary completion.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 30 months is above that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CORT118335